Suppression of Poxvirus Replication by Resveratrol
Authors:
Open Access
- 17 November 2017
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 8, 2196
Abstract
Poxviruses continue to cause serious diseases even after eradication of the historically deadly infectious human disease, smallpox. Poxviruses are currently being developed as vaccine vectors and cancer therapeutic agents. Resveratrol is a natural polyphenol stilbenoid found in plants that has been shown to inhibit or enhance replication of a number of viruses, but the effect of resveratrol on poxvirus replication is unknown. In the present study, we found that resveratrol dramatically suppressed the replication of vaccinia virus (VACV), the prototypic member of poxviruses, in various cell types. Resveratrol also significantly reduced the replication of monkeypox virus, a zoonotic virus that is endemic in Western and Central Africa and causes human mortality. The inhibitory effect of resveratrol on poxviruses is independent of VACV N1 protein, a potential resveratrol binding target. Further experiments demonstrated that resveratrol had little effect on VACV early gene expression, while it suppressed VACV DNA synthesis, and subsequently post-replicative gene expression.Keywords
Funding Information
- National Institute of General Medical Sciences (P20GM113117)
This publication has 55 references indexed in Scilit:
- Inhibitory Effect of Resveratrol against Duck Enteritis Virus In VitroPLOS ONE, 2013
- Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of CongoProceedings of the National Academy of Sciences, 2010
- Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencingProceedings of the National Academy of Sciences, 2010
- Vaccinia Virus Virulence Factor N1L is a Novel Promising Target for Antiviral Therapeutic InterventionJournal of Medicinal Chemistry, 2010
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- Nonhuman Primates Are Protected from Smallpox Virus or Monkeypox Virus Challenges by the Antiviral Drug ST-246Antimicrobial Agents and Chemotherapy, 2009
- ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose JustificationAntimicrobial Agents and Chemotherapy, 2009
- Identification of Novel Antipoxviral Agents: Mitoxantrone Inhibits Vaccinia Virus Replication by Blocking Virion AssemblyJournal of Virology, 2007
- Synergistic Efficacy of the Combination of ST-246 with CMX001 against OrthopoxvirusesAntimicrobial Agents and Chemotherapy, 2007
- Cidofovir Resistance in Vaccinia Virus Is Linked to Diminished Virulencein MiceJournal of Virology, 2006